摘要 |
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention concerns pharmaceutics, more specifically a prolonged-release composition of tedisamil or its pharmaceutically acceptable salt to be used in prevention and treatment of atrial fibrillation, atrial flutter and myocardial ischemia, containing 5 to 40 wt % of tedisamil or its pharmaceutically acceptable salt, 30 to 85 wt % of a water-swellable polymeric matrix containing hydroxypropylmethylcellulose (HPMC) of high or medium viscosity and hydrohyethyltcellulose (HEC) of high or medium viscosity in the ratio HPMC/HEC=1/0.85-1/1.2, 2.5 to 5 wt % of a salt capable to recover carbon-dioxide gas in the gastric medium, and 0.5 to 10 wt % of alginic acid. ^ EFFECT: invention allows providing tedisamil composition expressing improved bioavailability and causing less by-effects of gastrointestinal tract. ^ 5 cl, 6 ex, 4 tbl, 2 dwg |